72716-93-9

Usage

Uses

Used in Medicinal Chemistry Research:
5-[(6-methyl-3-pyridyl)methyl]-2-(nitroamino)-1H-pyrimidin-4-one is used as a research compound for exploring its potential biological activity. Its unique structure suggests that it may contribute to the development of new drugs, particularly in the pharmaceutical industry where novel compounds are constantly sought after for their therapeutic potential.
Used in Organic Synthesis:
In the field of organic chemistry, 5-[(6-methyl-3-pyridyl)methyl]-2-(nitroamino)-1H-pyrimidin-4-one is utilized as a precursor or building block. Its nitroamino group is of particular interest for further chemical modifications and the synthesis of more complex organic molecules, which could have applications in various chemical industries.

InChI:InChI=1/C11H11N5O3/c1-7-2-3-8(5-12-7)4-9-6-13-11(14-10(9)17)15-16(18)19/h2-3,5-6H,4H2,1H3,(H2,13,14,15,17)

Upstream product

• 556-88-7 nitroguanidine 
• 72716-92-8 2-formyl-3-(6-methyl-pyridin-3-yl)-propionic acid ethyl ester 
• 71351-48-9 3-(6-methyl-pyridin-3-yl)-propionic acid ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 72716-74-6 (E)-3-(6-Methyl-pyridin-3-yl)-acrylic acid ethyl ester 
• 72716-73-5 3-(6-methyl-3-pyridyl)acrylic acid 
• 53014-84-9 2-methyl-5-formylpyridine 

Downstream Products

• 93235-46-2 2-[2-(N-benzyl-N-pyrid-2-ylamino)ethylamino]-5-(6methylpyrid-3-ylmethyl) pyrimid-4-one 
• 83903-06-4 Lupitidine 
• 125767-21-7 2-(3-benzoylpropylamino)-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone dihydrochloride 
• 76517-95-8 2-<2-(5-methyl-4-imidazolylmethylthio)ethylamino>-5-(6-methylpyrid-3-yl)-4-pyrimidone 
• 125767-30-8 2-(4-phenyl-4,4-ethylenedioxybutylamino)-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone 
• 72717-05-6 2-<2-(2-furanylmethylthio)ethylamino>-5-(6-methyl-3-pyridylmethyl)pyrimidin-4-one 

Relevant academic research and scientific papers

Isocytosine H2-receptor histamine antagonists II. Synthesis and evaluation of biological activity at histamine H1- and H2-receptors of 5-(heterocyclyl)methylisocytosines

A series of 2--4-pyrimidones was synthesized based on oxmetidine 2, in which the methylenedioxyphenyl group of 2 was replaced by a heterocyclic ring.Good H2-receptor antagonist activity was retained over a range of basic and neutral heterocyclic substituents.Replacement of the 5-methyl-4-imidazolyl ring in selected compounds with 2-thiazolyl and, particularly, 3-bromo-2-pyridyl rings gave a series of compounds which have both H1- and H2-receptor histamine antagonist activities.Some structure-activity and structure-toxicity correlations are discussed.Compound 6d, 2--5-(6-methylpyrid-3-yl)-4-pyrimidone, has the most favourable combination of properties for H2-antagonism and has been evaluated further as an anti-secretory agent.

GUANIDINOTHIAZOLYL DERIVATIVES

The compounds are guanidinothiazolyl derivatives which are histamine H. sub.2-antagonists. A specific compound of the present invention is 2-2-(2-guanidino-4-thiazolylmethylthio)ethylamino!-5-(6-methyl-3-pyridylmethy l)-4-pyrimidone.

ISOUREAS AND ISOTHIOUREAS

The compounds are isoureas and isothioureas which have an O-or S-alkylpyrimidone substituent and which are histamine H 2-antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone.

Intermediates in the process for making histamine antagonists

A process for making substituted 2-aminopyrimidones which are histamine H2 - antagonists which comprises reacting a 2-nitroaminopyrimidone with a heteroarylalkylamine, heteroarylalkylthioalkylamine, or heteroarylalkoxyalkylamine. One particular compound which can be made by this process is 2-[2-(5-methyl-4-imidazolylmethylthio)ethylamino]-5-[5-(1,3-benzodioxolyl)methyl]-4-pyrimidone. Also claimed are 2-nitroaminopyrimidone intermediates for use in this process. One specific intermediate is 2-nitroamino-5-[5-(1,3-benzodioxolyl)methyl]-4-pyrimidone.

Pyrimidine compounds

The compounds are substituted pyrimidine compounds which are histamine H2 -antagonists. A specific compound of the present invention is 2-[2-(5-dimethylaminomethyl)-2-furylmethylthio)ethylamino]-5-(3-pyridylmethyl)-4-pyrimidone.